Treatment of patients with Paget's disease of bone.

作者: Christian Roux , Maxime Dougados

DOI: 10.2165/00003495-199958050-00005

关键词:

摘要: Paget's disease is a progressive bone disease, monostotic or polyostotic, characterised by hypertrophy of affected bones and accelerated disorganised remodelling. It results in deformities pain, with risk for articular neurological complications, fractures. The thus the therapeutic decision, function age patient, severity activity disease. Bisphosphonates are first-line therapy advent new bisphosphonates permits dramatic improvement treatment. optimal treatment regimen should obtain normalisation quasi-normalisation markers This result has potential long-term control

参考文章(82)
G. W. Divine, G. P. Jacobson, S. C. Patel, H. G. Bone, E. M. Monsell, C. W. Newman, D. D. Cody, Hearing loss in Paget's disease of bone: evidence of auditory nerve integrity. American Journal of Otology. ,vol. 16, pp. 27- 33 ,(1995)
Pierre J. Meunier, Alain Ravault, Treatment of Paget’s Disease with Etidronate Disodium Springer, Boston, MA. pp. 86- 99 ,(1991) , 10.1007/978-1-4684-2307-5_8
D. Hosking, P. J Meunier, J. D Ringe, J.-Y. Reginster, C. Gennari, Paget's disease of bone: diagnosis and management. BMJ. ,vol. 312, pp. 491- 494 ,(1996) , 10.1136/BMJ.312.7029.491
P.B. Greenberg, F.H. Doyle, M.T. Fisher, C.J. Hillyard, G.F. Joplin, J. Pennock, I. MacIntyre, Treatment of Paget's disease of bone with synthetic human calcitonin: biochemical and roentgenologic changes. The American Journal of Medicine. ,vol. 56, pp. 867- 870 ,(1974) , 10.1016/0002-9343(74)90816-X
Patrick Garnero, Christian Fledelius, Evelyne Gineyts, Claire-Marie Serre, Emanuelle Vignot, Pierre D. Delmas, Decreased β‐Isomerization of the C‐Terminal Telopeptide of Type I Collagen α1 Chain in Paget's Disease of Bone Journal of Bone and Mineral Research. ,vol. 12, pp. 1407- 1415 ,(1997) , 10.1359/JBMR.1997.12.9.1407
P. D. Delmas, B. Demiaux, L. Malaval, M. C. Chapuy, P. J. Meunier, Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone Calcified Tissue International. ,vol. 38, pp. 60- 61 ,(1986) , 10.1007/BF02556596
Luisa Alvarez, Nuria Guañabens, Pilar Peris, Ana Monegal, Jose L. Bedim, Ramon Deulofeu, M. Jesus Martinez de Osaba, Jose Muñoz-Gomez, Francisca Rivera-Fillat, Antonio M. Ballesta, Discriminative value of biochemical markers of bone turnover in assessing the activity of Paget's disease. Journal of Bone and Mineral Research. ,vol. 10, pp. 458- 465 ,(2009) , 10.1002/JBMR.5650100318
C A Mautalen, C A Casco, D Gonzalez, G R Ghiringhelli, C Massironi, G A Fromm, L Plantalech, Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases. BMJ. ,vol. 288, pp. 828- 829 ,(1984) , 10.1136/BMJ.288.6420.828-A
J.P. Devogelaer, J. Malghem, P. Stasse, C.Nagant De Deuxchaisnes, Biological and Radiological Responses to Oral Etidronate and Tiludronate in Paget's Disease of Bone Bone. ,vol. 20, pp. 259- 261 ,(1997) , 10.1016/S8756-3282(96)00368-7